International Business

EC Fines Bayer $3.88 Million: Referring to rules outlawing anti-competitive behavior, the European Commission said it decided to fine the German chemical giant for restricting foreign sales of its Adalat heart drug. The commission said the practices involved serious infringement of community law. It also said prices for Adalat varied widely from one EU country to another and that the price in Britain was considerably higher than in other member states, especially France and Spain. The commission said that before 1989 in Spain and 1991 in France, the main customers of the French and Spanish subsidiaries of Bayer ordered larger quantities of Adalat than needed for domestic use, exporting the surpluses to other EU states, including Britain.